Ignite Creation Date:
2025-12-25 @ 3:02 AM
Ignite Modification Date:
2025-12-31 @ 12:07 PM
Study NCT ID:
NCT05080933
Status:
COMPLETED
Last Update Posted:
2021-10-18
First Post:
2021-10-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
Sponsor:
University of Turin, Italy
Organization:
Study Overview
Official Title:
Extracorporeal Membrane Oxygenation for COVID-19 and Influenza H1N1 Associated Acute Respiratory Distress Syndrome: a Multi-centre Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
InfluCOV_ECMO
Brief Summary:
Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia. Little is known about outcome of these patients who required extracorporeal support.
Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS
Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: